Cargando…
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
BACKGROUND: As the first non‐factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. OBJECTIVES: We applied an algorithm for categorization of fatal events contemporaneous to emicizumab using reporter‐a...
Autores principales: | Peyvandi, Flora, Mahlangu, Johnny N., Pipe, Steven W., Hay, Charles R. M., Pierce, Glenn F., Kuebler, Peter, Kruse‐Jarres, Rebecca, Shima, Midori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756327/ https://www.ncbi.nlm.nih.gov/pubmed/33331041 http://dx.doi.org/10.1111/jth.15187 |
Ejemplares similares
-
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database
por: Pipe, Steven W., et al.
Publicado: (2020) -
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022) -
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023) -
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022) -
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)